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Abstract: BACKGROUND Coronary artery calcification is a marker of underlying atherosclerotic vascu-
lar disease. The absence of coronary artery calcification is associated with a low prevalence of obstructive
coronary artery disease (CAD), but it cannot be ruled out completely. We sought to develop a clinical tool
that can be added to Agatston score of zero to rule out obstructive CAD with high accuracy. METHODS
We developed a clinical score retrospectively from a cohort of 4903 consecutive patients with an Agatston
score of zero. Patients with prior diagnosis of CAD, coronary percutaneous coronary intervention, or
surgical revascularization were excluded. Obstructive CAD was defined as any epicardial vessel diameter
narrowing of ฀50%. The score was validated using an external cohort of 4290 patients with an Agatston
score of zero from a multinational registry. RESULTS The score consisted of 7 variables: age, sex, typical
chest pain, dyslipidemia, hypertension, family history, and diabetes mellitus. The model was robust with
an area under the curve of 0.70 (95% CI, 0.65-0.76) in the derivation cohort and 0.69 (95% CI, 0.65-0.72)
in the validation cohort. Patients were divided into 3 risk groups based on the score: low (฀6), interme-
diate (7-13), and high (฀14). Patients who score ฀6 have a negative likelihood ratio of 0.42 for obstructive
CAD, whereas those who score ฀14 have a positive likelihood ratio of >5.5 for obstructive CAD. The
outcome was ruled out in >98% of patients with a score ฀6 in the validation cohort. CONCLUSIONS
We developed a score that may be used to identify the likelihood of obstructive CAD in patients with
an Agatston score of zero, which may be used to direct the need for additional testing. However, the
results of this retrospective analysis are hypothesis generating and before clinical implementation should
be validated in a trial with a prospectively collected data.
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BACKGROUND: Coronary artery calcification is a marker of underlying 
atherosclerotic vascular disease. The absence of coronary artery 
calcification is associated with a low prevalence of obstructive coronary 
artery disease (CAD), but it cannot be ruled out completely. We sought to 
develop a clinical tool that can be added to Agatston score of zero to rule 
out obstructive CAD with high accuracy.
METHODS: We developed a clinical score retrospectively from a cohort of 
4903 consecutive patients with an Agatston score of zero. Patients with 
prior diagnosis of CAD, coronary percutaneous coronary intervention, or 
surgical revascularization were excluded. Obstructive CAD was defined 
as any epicardial vessel diameter narrowing of ≥50%. The score was 
validated using an external cohort of 4290 patients with an Agatston 
score of zero from a multinational registry.
RESULTS: The score consisted of 7 variables: age, sex, typical chest 
pain, dyslipidemia, hypertension, family history, and diabetes mellitus. 
The model was robust with an area under the curve of 0.70 (95% CI, 
0.65–0.76) in the derivation cohort and 0.69 (95% CI, 0.65–0.72) in 
the validation cohort. Patients were divided into 3 risk groups based on 
the score: low (≤6), intermediate (7–13), and high (≥14). Patients who 
score ≤6 have a negative likelihood ratio of 0.42 for obstructive CAD, 
whereas those who score ≥14 have a positive likelihood ratio of >5.5 for 
obstructive CAD. The outcome was ruled out in >98% of patients with a 
score ≤6 in the validation cohort.
CONCLUSIONS: We developed a score that may be used to identify the 
likelihood of obstructive CAD in patients with an Agatston score of zero, 
which may be used to direct the need for additional testing. However, the 
results of this retrospective analysis are hypothesis generating and before 
clinical implementation should be validated in a trial with a prospectively 
collected data.
© 2019 American Heart Association, Inc.
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C
oronary artery calcification (CAC) is a marker of 
underlying coronary artery atherosclerosis and an 
independent predictor of future cardiovascular 
events.1–4 The absence of CAC is prognostically impor-
tant and identifies a population at low risk of future 
cardiovascular events.1,2,5–9 Despite the low rates of fu-
ture cardiovascular events, the absence of CAC does 
not have sufficient negative predictive value for wide-
spread use as a single test for clinical risk stratification 
among symptomatic patients for whom there is a sus-
picion of obstructive coronary artery disease (CAD).10
Previous studies have demonstrated that, despite the 
absence of CAC, 1.4% to 7% of symptomatic individu-
als have obstructive CAD.11–13 Thus, clinicians are often 
unwilling to use the absence of CAC to halt additional 
testing in symptomatic patients with suspected CAD.
Image acquisition for CAC is routinely performed 
before coronary computed tomographic angiography 
(CCTA) and quantified using the Agatston method.14 
We sought to derive and validate a clinical tool that 
can be used in symptomatic patients without CAC 
(Agatston score, 0) to help to rule out obstructive CAD 
and potentially limit unnecessary downstream testing.
METHODS
Study Design and Eligibility
Using a cardiac computed tomography (CT) registry,15 we 
identified a derivation cohort comprised of patients with 
an Agatston score of zero who also underwent coronary 
CT angiography (CCTA). A nonoverlapping subgroup from 
Coronary CT Angiography Evaluation for Clinical Outcomes: 
an International Multicenter registry with Agatston score of 
zero was used for validation.16 We included only Coronary 
CT Angiography Evaluation for Clinical Outcomes: an 
International Multicenter registry centers with complete 
CCTA data and data on chest pain typicality and cardiac risk 
factors. Patients with a history of CAD, myocardial infarction, 
or revascularization were excluded. Additionally, we excluded 
patients being worked up for acute presentation with chest 
pain or to rule out acute coronary syndrome.
The study was approved by our institutional review 
board, and written, informed consents were obtained by all 
enrolled patients. Data supporting the findings of this study 
may be available from the corresponding author on reason-
able request.
Clinical Definitions
Clinical assessment done at the time of CCTA included medical 
history, physical findings, and available laboratory studies.15,16 
Chest pain typicality was defined according to the classifica-
tion proposed by Diamond and Forrester.17 The presence of 
cardiac risk factors was obtained through patient self-report-
ing and medical records. Hypertension was defined as known 
history of diagnosis of hypertension (systolic blood pressure 
≥140 mm Hg) or being treated for hypertension. Diabetes 
mellitus was defined as history of type I or type II diabetes 
mellitus or the use of hypoglycemic agents. Dyslipidemia was 
defined as a self-reported history of a known diagnosis of dys-
lipidemia or treatment with lipid-lowering agents. Family his-
tory of CAD was defined as diagnosis of CAD in a first-degree 
relative (age of <55 years for men and <65 years for women).
The pretest probability of obstructive CAD (≥50% luminal 
stenosis) was calculated for all patients according to age, sex, 
and typicality of chest pain using updated Diamond-Forrester 
risk model.18
Coronary Calcification and Computed 
Tomographic Angiography
CAC and CCTA images were acquired using single or dual 
source ≥64 slice CT scanners.15,16 Scans were interpreted by 
physician experts at each site.19,20 Coronary calcification was 
quantified using the Agatston method.14 Coronary artery seg-
mental luminal diameter was graded on a 4-point score (nor-
mal, mild [<50% stenosis], moderate [50%–69% stenosis], 
or severe [≥70% stenosis]), and patients with a stenosis of 
≥50% were categorized as having obstructive CAD. Because 
most of our data were collected before the publication of the 
CAD Reporting and Data System, minimal (1%–24%) and 
mild (25%–49%) stenoses were grouped together as a mild 
stenosis (0%–49%).10
Statistical Analysis
To compare the clinical characteristics of patients, we used 
Fisher exact test for categorical variables and t test for con-
tinuous variables. Categorical variables are presented as 
proportions with percentages, and continuous variables are 
presented as means with SDs. Statistical significance thresh-
old was set at P<0.05. Multiple imputations were performed 
for the missing values. Centers with large proportions of miss-
ing data on chest pain typicality or any of the risk factors for 
CAD were excluded from the validation cohort. All statistical 
procedures were performed using SAS 9.4 statistical software 
(SAS Institute, Cary, NC).
Model Derivation
To avoid data-driven model development, we specified our clin-
ical variables apriori.21 A group of practicing cardiologists was 
CLINICAL PERSPECTIVE
Traditionally, coronary artery calcification scoring 
has been used in the asymptomatic population to 
refine risk of future adverse cardiovascular events. 
Most recently, the American Heart Association 
issued guidelines for therapy based on coronary 
artery calcification. The utility of coronary artery 
calcification in the symptomatic population and 
how it may be used to guide downstream testing 
is lacking. The results of our study suggest that the 
combination of a clinical model and coronary artery 
calcification score of zero may effectively eliminate 
the need of additional testing. A prospective trial is 
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surveyed for 5 to 10 clinical predictors from a list of candidate 
clinical variables with potential association with CAD. This list 
included demographic data, known diagnoses and risk factors, 
symptoms, medications, physical assessment, and electrocar-
diographic findings. Clinical variables with the highest number 
of votes (age, sex, typical chest pain, hyperlipidemia, hyper-
tension, diabetes mellitus, current smoking, and family history) 
were included in a multivariable logistic regression model. 
Interaction between sex and other variables in the multivari-
able model was examined. Receiver operating characteristic 
curve for the multivariable model was generated. The discrim-
inative ability of the model was assessed using area under the 
curve and the corresponding C statistics. Model goodness of fit 
was assessed using Hosmer-Lemeshow statistics.
Development of the Scoring System
A point scoring system was derived from the proposed mul-
tivariable model based on the regression coefficients. We 
assigned points for each variable according to its regression 
coefficient, with 1 point for the smallest regression coef-
ficient, which served as the least common denominator for 
assigning point values for the score items. We used methods 
described by Sullivan et al22 and Le Gal et al.23 We computed 
the score for each patient and evaluated the classification 
ability of the developed score using the sensitivity, specific-
ity, positive and negative predictive values, and the likelihood 
ratios with CIs of each level of the score. We then defined 
the risk thresholds for low- and high-risk groups based on 
the negative and positive likelihood ratios, respectively, in a 
post hoc procedure. The calibration of the score was assessed 
by plotting the predicted risk of obstructive CAD against the 
observed one. The goodness of fit of the developed score was 
assessed using Hosmer-Lemeshow statistics where P>0.05 
indicates adequate fit of the score. We constructed a nomo-
gram of the developed risk score and a graphic plot of the 
risk score thresholds versus the likelihood ratio for clinical use 
(Figures I and II in the Data Supplement).
Score Validation
We applied the score externally and assessed the applicability 
of the scoring system in the validation cohort. We calculated 
the proportion of patients classified by the developed score 
and the observed risk of obstructive CAD for each risk group 
in the derivation and validation cohorts. We calculated the 
risk of all-cause mortality for each risk group in the validation 
cohort based on data of a median follow-up of 2 years.
RESULTS
A total of 44 125 consecutive patients (17 000 from the 
derivation cohort registry and 27 125 patients from the 
CONFIRM registry (Coronary CT Angiography Evalua-
tion for Clinical Outcomes: An International Multicenter) 
representing the validation cohort) were screened. After 
excluding patients with a history of CAD, coronary revas-
cularization, cardiac transplantation, and congenital 
heart disease, we identified 4903 eligible patients with 
an Agatston score of zero in the derivation cohort, with 
2.3% (n=112) having obstructive CAD (diameter steno-
sis, ≥50%). A nonoverlapping 8021 patients from Coro-
nary CT Angiography Evaluation for Clinical Outcomes: 
an International Multicenter registry were found with 
an Agatston score of zero. Centers with a large propor-
tion of missing data were excluded. The final validation 
cohort comprised of 4290 patients, with 4.8% (n=207) 
having obstructive CAD (Table  1). The proportion of 
imputed data was <5% of the total observations in both 
derivation and validation cohorts.
Derivation Cohort
The prespecification survey resulted in selection of age, 
sex, typical chest pain, family history, dyslipidemia, 
hypertension, and diabetes mellitus to be included in 
the multivariable logistic regression model (Table  2). 
Current smoking was excluded from the multivariable 
model because of the resulting paradoxical association 
between smoking and the outcome of obstructive CAD, 
which is clinically nonplausible. There was insignificant 
interaction between sex and other variables. The pro-
posed model had an area under the receiver operating 
characteristic curve of 0.70 (95% CI, 0.65–0.76) in the 
derivation cohort (Figure 1A).
Score Development
Each variable was assigned a value derived from the 
corresponding regression coefficient in the multivari-
able model (Table  3). Based on the generated score 
(range, 0–20), the predicted probability for prevalence 
of obstructive CAD ranged from 0.45% (95% CI, 0.26–
0.77) to 18% (95% CI, 10.78–28.30). The diagnostic 
ability for each score threshold in the model was calcu-
lated (Table 4), and thresholds were grouped into 3 cat-
egories (low [≤6], intermediate [7–13], and high [≥14]) 
based on the positive and negative likelihood ratios 
(Table 5). Patients with a score of ≤6 have a high nega-
tive predictive value (99%) and a low negative likelihood 
ratio (0.42; Table 5). Conversely, patients for whom the 
score was ≥14 have a specificity of 98% and a positive 
likelihood ratio of >5 for obstructive CAD (Table 5).
Score Validation
Using an external validation cohort, the score demon-
strated an acceptable discriminative performance with 
an area under the receiver operating characteristic 
curve of 0.69 (95% CI, 0.65–0.72; Figure 1B). The pro-
portion of patients in each risk category in the valida-
tion cohort is similar to that in the derivation cohort 
but slightly higher prevalence of obstructive CAD con-
sistent with the overall higher prevalence of obstructive 
CAD in the validation cohort (Table 5). The score had 
a good calibration between predicted and observed 
risks of obstructive CAD in the derivation and valida-
tion cohorts particularly at low- and intermediate-risk 
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the low- and intermediate-risk groups in the validation 
cohort was 0.51% and 0.58%, respectively, compared 
with 2% in the high-risk group (P=0.02).
When we included symptomatic patients only, there 
was no significant difference in the discriminative per-
formance of the score with an area under the receiver 
operating characteristic curve of 0.67 in both the deri-
vation (95% CI, 0.62–0.73) and validation (95% CI, 
0.62–0.71) cohorts.
DISCUSSION
The results of our analysis demonstrate that not all 
patients with a zero calcium score are equal. Our 
model demonstrates that an Agatston score of zero 
can be used to exclude obstructive CAD but also 
identify a group where CAC alone cannot be used to 
exclude CAD.
This project is novel because it addresses an unmet 
need of how a zero calcium score can be incorporated 
into a clinical strategy among patients with suspected 
CAD so that additional testing might be averted. The 
developed tool includes clinical variables that are readily 
available for most of the patients on clinical assessment 
and calcium score quantification performance. The rela-
tionship between current smoking and the outcome of 
obstructive CAD in our multivariable model was not clin-
ically plausible, and thus current smoking was excluded 
Table 2. Multivariable Clinical Model for Obstructive Coronary Artery Disease
β SE Odds Ratio Lower CI Upper CI P Value
Intercept −5.3101 0.6457 … … …  
Age, y 0.00935 0.0104 1.009 0.989 1.030 0.3665
Men 0.8024 0.2105 2.231 1.477 3.370 0.0001
Typical chest pain 1.0549 0.2779 2.872 1.666 4.950 0.0001
Hyperlipidemia 0.6276 0.2077 1.873 1.247 2.814 0.0025
Hypertension 0.2091 0.2011 1.233 0.831 1.828 0.2984
Family history 0.2331 0.1971 1.262 0.858 1.858 0.2370
Diabetes mellitus 0.1597 0.2954 1.173 0.657 2.093 0.5889
Table 1. Clinical Characteristics of Derivation and Validation Cohorts








 (n=207) P Value*
Age, y 53±10.3 53±10 0.588 52±12 60±12 0.0001
Men 1993 (42) 65 (58) 0.0006 1967 (48) 111 (54) 0.100
Pretest probability of CAD 0.21±0.36 0.32±0.32 0.003 0.30±0.26 0.36±0.29 0.006
Body mass index, kg/m2 29±6 30±5 0.412 28±5 29±6 0.007
Chest pain   0.0002   0.164
  Typical 370 (8) 22 (20)  407 (10) 23 (11)  
  Atypical/noncardiac 2628 (55) 51 (46)  2151 (53) 87 (54)
Shortness of breath 2935 (61) 61 (54) 0.250 792 (19) 47 (23) 0.023
Asymptomatic 871 (18) 16 (14) 0.113 1111 (27) 57 (25) 0.124
Family history 2194 (46) 56 (50) 0.389 1481 (36) 100 (49) 0.001
Hypertension 1838 (38) 54 (48) 0.040 1544 (38) 104 (51) 0.0003
Hyperlipidemia 1970 (41) 67 (60) 0.0001 1644 (40) 129 (63) 0.0001
Current smoking 650 (14) 15 (13) 0.820 663 (16) 32 (16) 0.922
Diabetes mellitus 432 (9) 15 (13) 0.132 299 (7) 43 (21) 0.0001
Aspirin 2010 (42) 63 (56) 0.004 700 (17) 30 (15) 0.002
β-Blockers 1601 (33) 47 (42) 0.068 663 (16) 19 (9) 0.560
Lipid-lowering agents 1408 (29) 49 (44) 0.002 587 (14) 25 (2) 0.043
Resting ECG
  Ischemic changes† 1334 (28) 23 (21) 0.108 NA NA  
CAD indicates coronary artery disease.
*P value was calculated based on effective sample size.
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from our tool. This paradoxical relationship could be 
due to issues surrounding data collection and classifica-
tion of smoking status. Younger patients who smoke 
but with an overall lower risk profile are more likely to 
be referred for CCTA although there was no interaction 
between current smoking and other variables in our 
model. Model specification was done a priori through 
surveying a group of practicing cardiologists to avoid 
data-driven selection of predictors and model overfit-
ting.24 We used the likelihood ratios for risk classification 
given the low prevalence of the outcome in the deriva-
tion cohort (2%) and the limitations of the sensitivity 
and specificity in such case. When validated externally in 
a multicenter cohort, it showed an acceptable discrimi-
native and classification performance. This indicates 
both validity and transportability of the developed score. 
Our score appeared to be more useful in identifying the 
group with low probability of having obstructive CAD 
and thereby can be used as a tool to guide the down-
stream testing in this group. Prognostically, patients in 
the low- and intermediate-risk groups had a lower risk 
of all-cause mortality compared with those in the higher 
risk group when followed up for a median follow-up 
time of 2 years in the validation cohort.
Coronary Artery Calcification
CAC has important diagnostic and prognostic implica-
tions. CAC is a marker of atherosclerotic disease and is 
associated with future cardiovascular events and all-cause 
mortality.1–5,25,26 When added to conventional risk factors, 
calcium score improves the performance of prediction 
models for cardiovascular events and improves the reclas-
sification of individuals’ risks. Adding the Agatston score 
to the Framingham risk score led to significant reclassifi-
cation of individuals to higher or lower risk categories.27–30
Clinical Utility of an Agatston Score of 
Zero
The Agatston score of zero has been investigated in sev-
eral studies of asymptomatic and symptomatic partici-
pants.1,2,4–6 Raggi et al5 reported low annual coronary event 
rates of 0.11% for Agatston score of zero compared with 
4.8% for score of ≥400 in asymptomatic patients. Among 
3409 patients with Agatston score of zero in the MESA 
(Multi-Ethnic Study of Atherosclerosis), only 0.4% devel-
Figure 1. Receiver operating characteristic (ROC) curve of the model to predict obstructive coronary artery disease in derivation and validation cohorts. 
Our model has an area under the ROC curve of 0.70 (CI, 0.65–0.76) in the derivation cohort (A) and 0.69 (95% CI, 0.65–0.72) in the validation cohort (B), which 
demonstrates a robust discriminative ability.
Table 3. Obstructive CAD Score in Patients With Agatston Score of Zero
Variable Scoring Point
Age, y
  <30 0
  30–39 1
  40–49 2
  50–59 3
  60–69 4
  ≥70 5
Men 4
Typical chest pain 5
Dyslipidemia 3
Hypertension 1
Family history of CAD 1
Diabetes mellitus 1
Clinical probability: low risk, ≤6 points; intermediate risk, 7 to 13 points; 
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oped any coronary event during the follow-up period of 3 
years versus an event rate of 8% for those with Agatston 
score ≥300.4 Despite the prognostic utility of zero calcium 
score as proven by the low cardiovascular event rates, the 
presence of obstructive CAD among these patients can-
not be absolutely ruled out. Several earlier studies report-
ed a prevalence of obstructive CAD in patients with zero 
calcium score that varied widely from 7% to 38%.11,31–34 
This is likely explained by the high-risk presentations of 
populations studied and technology used. Villines et al12 
reported a prevalence of 3.5% of obstructive CAD among 
patients with an Agatston score of zero. More recently, 
Mittal et al13 reported a lower prevalence rate of obstruc-
tive CAD in patients with zero calcium score of 1.4% in a 
cohort of mostly asymptomatic patients and patients with 
atypical presentation.
The diagnostic uncertainty of an Agatston score 
of zero has limited its clinical use to rule out obstruc-
tive CAD. Our proposed clinical risk score when com-
bined with calcium score can improve the diagnostic 
utility of an Agatston score of zero by allowing it to 
rule out obstructive CAD with a negative predictive 
value of 99%. Based on the performance of this risk 
score, we propose a new management algorithm for 
workup of suspected CAD when CCTA is considered 
(Figure 3). For patients presenting for CCTA to rule 
out obstructive CAD, those with a low risk score 
(≤6), an Agatston score be performed. In those with 
an Agatston score of zero, the presence of obstruc-
tive CAD can be ruled out with high certainty. Theo-
retically, this approach will result in lower radiation 
exposure, eliminate the need for contrast media, and 
reduce healthcare costs.
Conversely, this model could also be used to iden-
tify patients who may require further testing. Those 
symptomatic patients with an Agatston score of zero 
Table 5. Proportions of Patients Classified by Obstructive CAD Risk Score Among Patients With Agatston Score of Zero and 
Predictive Accuracy of the Score
Clinical Score
Derivation Cohort Validation Cohort
Total Patients, n (%)
Confirmed Obstructive 
CAD, n (%) Total Patients, n (%)
Confirmed Obstructive 
CAD, n (%)
Low risk, ≤6 2090 (42.63) 24 (1.15) 1736 (40.50) 34 (1.96)
Intermediate risk, 7–13 2699 (55.05) 75 (2.78) 2407 (56.11) 152 (6.31)
High risk, ≥14 114 (2.32) 13 (11.40) 147 (3.40) 19 (12.93)
CAD indicates coronary artery disease.
Table 4. Operating Characteristics for Thresholds of Obstructive Coronary Artery Disease Score
Score Sensitivity Specificity PPV NPV PLR NLR
0 1.00 (0.999 to 1.000) 0.0 0.023 (0.019 to 0.027) … 1.00 …
1 1.00 (0.979 to 1.000) 0.002 (0.001 to 0.004) 0.023 (0.019 to 0.027) 1.000 (0.720 to 1.000) 1.00 …
2 0.99 (0.958 to 1.000) 0.010 (0.008 to 0.014) 0.023 (0.019 to 0.028) 0.980 (0.894 to 1.000) 1.001 (0.982 to 1.020) 0.877 (−0.953 to 2.699)
3 0.98 (0.948 to 1.000) 0.049 (0.044 to 0.056) 0.024 (0.019 to 0.028) 0.992 (0.970 to 1.000) 1.033 (1.005 to 1.062) 0.358 (−0.165 to 0.887)
4 0.96 (0.911 to 0.990) 0.133 (0.124 to 0.143) 0.025 (0.020 to 0.030) 0.994 (0.984 to 0.998) 1.112 (1.068 to 1.157) 0.268 (−0.006 to 0.542)
5 0.884 (0.810 to 0.937) 0.237(0.225 to 0.249) 0.026 (0.022 to 0.032) 0.989 (0.981 to 0.994) 1.158 (1.073 to 1.242) 0.490 (0.223 to 0.758)
6 0.866 (0.789 to 0.923) 0.318 (0.305 to 0.331) 0.029 (0.023 to 0.035) 0.990 (0.984 to 0.995) 1.269 (1.168 to 1.371) 0.421 (0.210 to 0.633)
7 0.786 (0.698 to 0.858) 0.431 (0.417 to 0.445) 0.031 (0.025 to 0.038) 0.990 (0.983 to 0.993) 1.381 (1.235 to 1.528) 0.497 (0.309 to 0.865)
8 0.679 (0.584 to 0.764) 0.577 (0.563 to 0.591) 0.036 (0.029 to 0.045) 0.990 (0.982 to 0.992) 1.605 (1.380 to 1.829) 0.557 (0.397 to 0.716)
9 0.563 (0.466 to 0.656) 0.703 (0.690 to 0.716) 0.042 (0.033 to 0.054) 0.987 (0.981 to 0.989) 1.895 (1.555 to 2.235) 0.622 (0.483 to 0.761)
10 0.473 (0.378 to 0.570 0.794 (0.782 to 0.805) 0.051 (0.038 to 0.066) 0.985 (0.980 to 0.988) 2.292 (1.798 to 2.786) 0.664 (0.540 to 0.788)
11 0.393 (0.302 to 0.490) 0.865 (0.855 to 0.874) 0.064 (0.047 to 0.084) 0.984 (0.980 to 0.987) 2.905 (2.162 to 3.648) 0.702 (0.591 to 0.813)
12 0.214 (0.142 to 0.302) 0.918 (0.910 to 0.925) 0.057 (0.037 to 0.084) 0.980 (0.976 to 0.984) 2.606 (1.591 to 3.620) 0.856 (0.768 to 0.944)
13 0.143 (0.084 to 0.222) 0.958 (0.952 to 0.964) 0.074 (0.043 to 0.117) 0.980 (0.975 to 0.983) 3.405 (1.694 to 5.115) 0.894 (0.822 to 0.967)
14 0.116 (0.63 to 0.190) 0.979 (0.974 to 0.983) 0.114 (0.062 to 0.187) 0.979 (0.975 to 0.983) 5.505 (2.312 to 8.697) 0.903 (0.839 to 0.967)
15 0.063 (0.026 to 0.124) 0.987 (0.983 to 0.990) 0.100 (0.041 to 0.195) 0.978 (0.973 to 0.982) 4.753 (0.930 to 8.576) 0.950 (0.902 to 0.998)
16 0.027 (0.006 to 0.076) 0.991 (0.988 to 0.993) 0.064 (0.013 to 0.175) 0.978 (0.973 to 0.982) 2.917 (0.656 to 6.489) 0.982 (0.950 to 1.014)
17 0.018 (0.002 to 0.063) 0.996 (0.993 to 0.997) 0.087 (0.012 to 0.280) 0.978 (0.972 to 0.981) 4.074 (−2.143 to 10.291) 0.986 (0.960 to 1.013)
18 0.009 (0.002 to 0.049) 1.000 (0.998 to 1.000) 0.333 (0.008 to 0.906) 0.977 (0.973 to 0.981) 21.38 (−32.921 to 75.698) 0.992 (0.973 to 1.010)
19 0.0 1.000 (0.998 to 1.000) … 0.977 (0.973 to 0.981) 0.00 1.009 (0.810 to 1.208)
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and a score >6 should proceed with CCTA or other 
testing since obstructive CAD cannot be excluded. 
As an example, a 50-year-old symptomatic man and 
a 50-year-old woman with 2 risk factors would both 
have an intermediate-risk score, despite having an 
Agatston score of zero.
Limitations
The definition of obstructive CAD was based on the 
findings from CCTA; therefore, false-positive and false-
negative cases are possible. Because most of CCTA 
studies were performed before the publication of the 
CAD Reporting and Data System, some of the includ-
ed patients with typical symptoms may have had long 
lesions or large volume plaque with luminal stenosis 
<50%, which could result in ischemia. For the devel-
opment of our model, we used data collected retro-
spectively from a tertiary-care center where functional 
testing for CAD and invasive coronary angiogram are 
easily accessible; this may introduce referral bias as the 
cohort has an overall lower risk of obstructive CAD. 
Our validation dataset was a subgroup with low rates 
of missing values from a larger international registry. 
Exclusion of other centers could have affected the rep-
resentation of the validation cohort. The results of this 
retrospective analysis are hypothesis generating and 
before clinical implementation, should be validated in a 
trial with a prospectively collected data.
Conclusions
We developed a score that may be used to identify 
the likelihood of obstructive CAD in patients with an 
Agatston score of zero, which may be used to direct 
the need for additional testing. However, the results 
of this retrospective analysis are hypothesis generating 
and before clinical implementation, should be validated 
in a trial with a prospectively collected data.
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Figure 3. Proposed algorithm for work up of obstructive coronary 
artery disease (CAD) based on the obstructive CAD risk score.  
The proposed algorithm provides an illustration of the use of the obstructive 
CAD risk score as a clinical decision tool. In patients with zero calcium score, 
patients with a score of ≤6 points, further testing may not be needed as 
































Circ Cardiovasc Imaging. 2019;12:e008737. DOI: 10.1161/CIRCIMAGING.118.008737 September 2019 8
Alshahrani et al; Diagnostic Utility of an Agatston Score of Zero
Cardiac and Vascular Institute, Miami, FL (R.C.C.). Capitol Cardiology Associ-
ates, Albany, NY (A.D.). Department of Radiology, Medical University of Inns-
bruck, Austria (G.F.). Department of Radiology and Nuclear Medicine, German 
Heart Center Munich, Germany (M.H.). Medizinische Klinik I der Ludwig-Max-
imilians-UniversitätMünchen, Munich, Germany (J.H.). University Hospital, 
Zurich, Switzerland (P.A.K.). Seoul National University Hospital, South Korea 
(Y.-J.K.). Department of Medicine and Radiology, University of British Colum-
bia, Vancouver, Canada (J.A.L.). Department of Radiology, Area Vasta 1/ASUR 
Marche, Urbino, Italy (E.M.). Unit of Cardiovascular Imaging, Hospital da Luz, 
Lisboa, Portugal (H. Marques). William Beaumont Hospital, Royal Oaks, MI 
(K.C., G.R.). Department of Cardiology at the Lady Davis Carmel Medical 
Center, The Ruth and Bruce Rappaport School of Medicine, Technion-Israel 
Institute of Technology, Haifa, Israel (R.R.). Department of Radiology (L.J.S.) 
and Department of Radiology (F.Y.L., J.K.M.), New York-Presbyterian Hospital 
and the Weill Cornell Medical College. Department of Medicine, Walter Reed 
Medical Center, Washington, DC (T.C.V.). Department of Medicine, Walter 
Reed National Military Medical Center, Bethesda, MD (T.C.V.).
Disclosures
Dr Budoff receives grant support from General Electric. Dr Leipsic serves as a 
consultant and has stock options with Circle Cardiovascular Imaging and Heart-
flow. Dr Min receives research support from National Institutes of Health, Gen-
eral Electric Healthcare, and Dalio Foundation; serves on the advisory board for 
General Electric Healthcare and Arineta; and has ownership interest with Cleer-
ly. Dr Chow receives research support from CV Diagnostix and Ausculsciences; 
educational support from TeraRecon, Inc; and has equity interest in General 
Electric. The other authors report no conflicts.
REFERENCES
 1. LaMonte MJ, FitzGerald SJ, Church TS, Barlow CE, Radford NB, Levine 
BD, Pippin JJ, Gibbons LW, Blair SN, Nichaman MZ. Coronary artery cal-
cium score and coronary heart disease events in a large cohort of as-
ymptomatic men and women. Am J Epidemiol. 2005;162:421–429. doi: 
10.1093/aje/kwi228
 2. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O’Malley PG. 
Coronary calcium independently predicts incident premature coro-
nary heart disease over measured cardiovascular risk factors: mean 
three-year outcomes in the Prospective Army Coronary Calcium 
(PACC) project. J Am Coll Cardiol. 2005;46:807–814. doi: 10.1016/j. 
jacc.2005.05.049
 3. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary ar-
tery calcium score to predict coronary heart disease events: a systematic 
review and meta-analysis. Arch Intern Med. 2004;164:1285–1292. doi: 
10.1001/archinte.164.12.1285
 4. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, 
Shea S, Szklo M, Bluemke DA, O’Leary DH, Tracy R, Watson K, Wong 
ND, Kronmal RA. Coronary calcium as a predictor of coronary events in 
four racial or ethnic groups. N Engl J Med. 2008;358:1336–1345. doi: 
10.1056/NEJMoa072100
 5. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data 
to develop models for prediction of hard coronary events. Am Heart J. 
2001;141:375–382. doi: 10.1067/mhj.2001.113220
 6. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcifica-
tion, coronary disease risk factors, C-reactive protein, and atherosclerotic 
cardiovascular disease events: the St. Francis Heart Study. J Am Coll Car-
diol. 2005;46:158–165. doi: 10.1016/j.jacc.2005.02.088
 7. Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Hoffman 
U, Cury RC, Abbara S, Brady TJ, Budoff MJ, Blumenthal RS, Nasir K.  
Diagnostic and prognostic value of absence of coronary artery calci-
fication. JACC Cardiovasc Imaging. 2009;2:675–688. doi: 10.1016/j. 
jcmg.2008.12.031
 8. Al-Mallah MH, Qureshi W, Lin FY, Achenbach S, Berman DS, Budoff MJ, 
Callister TQ, Chang HJ, Cademartiri F, Chinnaiyan K, Chow BJ, Cheng 
VY, Delago A, Gomez M, Hadamitzky M, Hausleiter J, Kaufmann PA, 
Leipsic J, Maffei E, Raff G, Shaw LJ, Villines TC, Cury RC, Feuchtner G, 
Plank F, Kim YJ, Dunning AM, Min JK. Does coronary CT angiography 
improve risk stratification over coronary calcium scoring in symptomatic 
patients with suspected coronary artery disease? Results from the pro-
spective multicenter international CONFIRM registry. Eur Heart J Cardio-
vasc Imaging. 2014;15:267–274. doi: 10.1093/ehjci/jet148
 9. Blaha MJ, Cainzos-Achirica M, Greenland P, McEvoy JW, Blankstein R, 
Budoff MJ, Dardari Z, Sibley CT, Burke GL, Kronmal RA, Szklo M, Blu-
menthal RS, Nasir K. Role of coronary artery calcium score of zero and 
other negative risk markers for cardiovascular disease: the Multi-Ethnic 
Study of Atherosclerosis (MESA). Circulation. 2016;133:849–858. doi: 
10.1161/CIRCULATIONAHA.115.018524
 10. Schenker MP, Dorbala S, Hong EC, Rybicki FJ, Hachamovitch R, Kwong 
RY, Di Carli MF. Interrelation of coronary calcification, myocardial isch-
emia, and outcomes in patients with intermediate likelihood of coro-
nary artery disease: a combined positron emission tomography/com-
puted tomography study. Circulation. 2008;117:1693–1700. doi: 
10.1161/CIRCULATIONAHA.107.717512
 11. Rubinshtein R, Gaspar T, Halon DA, Goldstein J, Peled N, Lewis BS. Preva-
lence and extent of obstructive coronary artery disease in patients with 
zero or low calcium score undergoing 64-slice cardiac multidetector com-
puted tomography for evaluation of a chest pain syndrome. Am J Cardiol. 
2007;99:472–475. doi: 10.1016/j.amjcard.2006.08.060
 12. Villines TC, Hulten EA, Shaw LJ, Goyal M, Dunning A, Achenbach S, 
Al-Mallah M, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang 
HJ, Cheng VY, Chinnaiyan K, Chow BJ, Delago A, Hadamitzky M, 
Hausleiter J, Kaufmann P, Lin FY, Maffei E, Raff GL, Min JK; CON-
FIRM Registry Investigators. Prevalence and severity of coronary ar-
tery disease and adverse events among symptomatic patients with 
coronary artery calcification scores of zero undergoing coronary com-
puted tomography angiography: results from the CONFIRM (coronary 
CT angiography evaluation for clinical outcomes: an international 
multicenter) registry. J Am Coll Cardiol. 2011;58:2533–2540. doi: 
10.1016/j.jacc.2011.10.851
 13. Mittal TK, Pottle A, Nicol E, Barbir M, Ariff B, Mirsadraee S, Dubowitz M, 
Gorog DA, Clifford P, Firoozan S, Smith R, Dubrey S, Chana H, Shah J, 
Stephens N, Travill C, Kelion A, Pakkal M, Timmis A. Prevalence of obstruc-
tive coronary artery disease and prognosis in patients with stable symp-
toms and a zero-coronary calcium score. Eur Heart J Cardiovasc Imaging. 
2017;18:922–929. doi: 10.1093/ehjci/jex037
 14. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, 
Detrano R. Quantification of coronary artery calcium using ultrafast 
computed tomography. J Am Coll Cardiol. 1990;15:827–832. doi: 
10.1016/0735-1097(90)90282-t
 15. Chow BJ, Wells GA, Chen L, Yam Y, Galiwango P, Abraham A, Sheth 
T, Dennie C, Beanlands RS, Ruddy TD. Prognostic value of 64-slice car-
diac computed tomography severity of coronary artery disease, coronary 
atherosclerosis, and left ventricular ejection fraction. J Am Coll Cardiol. 
2010;55:1017–1028. doi: 10.1016/j.jacc.2009.10.039
 16. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah MH, Berman DS, 
Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Cheng V, Chin-
naiyan KM, Chow B, Delago A, Hadamitzky M, Hausleiter J, Karls-
berg RP, Kaufmann P, Maffei E, Nasir K, Pencina MJ, Raff GL, Shaw 
LJ, Villines TC. Rationale and design of the CONFIRM (Coronary CT 
Angiography Evaluation for Clinical Outcomes: an International Mul-
ticenter) registry. J Cardiovasc Comput Tomogr. 2011;5:84–92. doi: 
10.1016/j.jcct.2011.01.007
 17. Diamond GA, Forrester JS. Analysis of probability as an aid in the clini-
cal diagnosis of coronary-artery disease. N Engl J Med. 1979;300:1350–
1358. doi: 10.1056/NEJM197906143002402
 18. Genders TS, Steyerberg EW, Alkadhi H, Leschka S, Desbiolles L, Nieman 
K, Galema TW, Meijboom WB, Mollet NR, de Feyter PJ, Cademartiri F, 
Maffei E, Dewey M, Zimmermann E, Laule M, Pugliese F, Barbagallo R, 
Sinitsyn V, Bogaert J, Goetschalckx K, Schoepf UJ, Rowe GW, Schuijf JD, 
Bax JJ, de Graaf FR, Knuuti J, Kajander S, van Mieghem CA, Meijs MF, 
Cramer MJ, Gopalan D, Feuchtner G, Friedrich G, Krestin GP, Hunink 
MG; CAD Consortium. A clinical prediction rule for the diagnosis of 
coronary artery disease: validation, updating, and extension. Eur Heart J. 
2011;32:1316–1330. doi: 10.1093/eurheartj/ehr014
 19. Raff GL, Abidov A, Achenbach S, Berman DS, Boxt LM, Budoff MJ, 
Cheng V, DeFrance T, Hellinger JC, Karlsberg RP; Society of Cardio-
vascular Computed Tomography. SCCT guidelines for the interpreta-
tion and reporting of coronary computed tomographic angiography. 
J Cardiovasc Comput Tomogr. 2009;3:122–136. doi: 10.1016/j.jcct. 
2009.01.001
 20. Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, Nieman K, 
Pontone G, Raff GL. SCCT guidelines for the interpretation and reporting 
of coronary CT angiography: a report of the society of cardiovascular com-
































Circ Cardiovasc Imaging. 2019;12:e008737. DOI: 10.1161/CIRCIMAGING.118.008737 September 2019 9
Alshahrani et al; Diagnostic Utility of an Agatston Score of Zero
 21. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression 
modelling strategies for improved prognostic prediction. Stat Med. 
1984;3:143–152.
 22. Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate 
data for clinical use: the framingham study risk score functions. Stat Med. 
2004;23:1631–1660. doi: 10.1002/sim.1742
 23. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, 
Perrier A. Prediction of pulmonary embolism in the emergency depart-
ment: the revised Geneva score. Ann Intern Med. 2006;144:165–171. 
doi: 10.7326/0003-4819-144-3-200602070-00004
 24. Harrell FE Jr. Multivariable Modeling Strategies. Regression Modeling 
Strategies-With Applications to Linear Models, Logistic Regression, and 
Survival Analysis. New York, NY; Springer; 2001:53–85.
 25. Al Rifai M, McEvoy JW, Nasir K, Rumberger J, Feldman D, Budoff 
MJ, Blaha MJ. Traditional cardiovascular disease risk factors associ-
ated with one-year all-cause mortality among those with coronary ar-
tery calcium scores ≥400. Atherosclerosis. 2015;241:495–497. doi: 
10.1016/j.atherosclerosis.2015.06.002
 26. Budoff MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, Demoss 
D, Nuguri V, Nabavi V, Ratakonda R, Berman DS, Raggi P. Progression of 
coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Im-
aging. 2010;3:1229–1236. doi: 10.1016/j.jcmg.2010.08.018
 27. Elias-Smale SE, Proença RV, Koller MT, Kavousi M, van Rooij FJ, Hunink 
MG, Steyerberg EW, Hofman A, Oudkerk M, Witteman JC. Coronary cal-
cium score improves classification of coronary heart disease risk in the 
elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56:1407–1414. doi: 
10.1016/j.jacc.2010.06.029
 28. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang  
A, Dragano N, Grönemeyer D, Seibel R, Kälsch H, Bröcker-Preuss M, Mann K, 
Siegrist J, Jöckel KH; Heinz Nixdorf Recall Study Investigative Group. Coronary 
risk stratification, discrimination, and reclassification improvement based on 
quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall 
study. J Am Coll Cardiol. 2010;56:1397–1406. doi: 10.1016/j.jacc.2010.06.030
 29. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci 
AD, Greenland P. Coronary artery calcium score and risk classification 
for coronary heart disease prediction. JAMA. 2010;303:1610–1616. doi: 
10.1001/jama.2010.461
 30. McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal 
RA, Bild DE, Shea S, Liu K, Watson KE, Folsom AR, Khera A, Ayers C, 
Mahabadi AA, Lehmann N, Jöckel KH, Moebus S, Carr JJ, Erbel R, Burke 
GL. 10-Year coronary heart disease risk prediction using coronary ar-
tery calcium and traditional risk factors: derivation in the MESA (Multi-
Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nix-
dorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 
2015;66:1643–1653. doi: 10.1016/j.jacc.2015.08.035
 31. Haberl R, Tittus J, Böhme E, Czernik A, Richartz BM, Buck J, Steinbigler 
P. Multislice spiral computed tomographic angiography of coronary arter-
ies in patients with suspected coronary artery disease: an effective filter 
before catheter angiography? Am Heart J. 2005;149:1112–1119. doi: 
10.1016/j.ahj.2005.02.048
 32. Gottlieb I, Miller JM, Arbab-Zadeh A, Dewey M, Clouse ME, Sara L, Niinu-
ma H, Bush DE, Paul N, Vavere AL, Texter J, Brinker J, Lima JA, Rochitte CE. 
The absence of coronary calcification does not exclude obstructive coro-
nary artery disease or the need for revascularization in patients referred 
for conventional coronary angiography. J Am Coll Cardiol. 2010;55:627–
634. doi: 10.1016/j.jacc.2009.07.072
 33. Cademartiri F, Maffei E, Palumbo A, Martini C, Seitun S, Tedeschi C, 
De Rosa R, Arcadi T, Salamone I, Blandino A, Weustink AC, Mollet NR, 
De Feyter PJ, Krestin GP. Diagnostic accuracy of computed tomography 
coronary angiography in patients with a zero calcium score. Eur Radiol. 
2010;20:81–87. doi: 10.1007/s00330-009-1529-9
 34. Akram K, O’Donnell RE, King S, Superko HR, Agatston A, Voros S. In-
fluence of symptomatic status on the prevalence of obstructive coro-
nary artery disease in patients with zero calcium score. Atherosclerosis. 
2009;203:533–537. doi: 10.1016/j.atherosclerosis.2008.07.008
D
o
w
n
lo
ad
ed
 fro
m
 h
ttp
://ah
ajo
u
rn
als.o
rg
 b
y
 o
n
 F
eb
ru
ary
 7
, 2
0
2
0
